TQB3455

TQB3455 is a novel, orally bioavailable small molecule inhibitor that selectively targets mutated isocitrate dehydrogenase 2 (IDH2), an enzyme implicated in the pathogenesis of certain hematological malignancies. By inhibiting mutant IDH2, TQB3455 aims to reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), thereby restoring normal cellular differentiation and exerting antitumor effects. The drug has demonstrated preliminary antitumor activity and tolerability in early-phase clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) harboring IDH2 mutations. It is being evaluated both as monotherapy and in combination with azacitidine, particularly for patients who are newly diagnosed with mutant-IDH2 AML or MDS and are not eligible for intensive chemotherapy.